CN1679822A - Oral medicine for treating hyperlipemia - Google Patents
Oral medicine for treating hyperlipemia Download PDFInfo
- Publication number
- CN1679822A CN1679822A CN 200510041627 CN200510041627A CN1679822A CN 1679822 A CN1679822 A CN 1679822A CN 200510041627 CN200510041627 CN 200510041627 CN 200510041627 A CN200510041627 A CN 200510041627A CN 1679822 A CN1679822 A CN 1679822A
- Authority
- CN
- China
- Prior art keywords
- present
- medicine
- crude drug
- zanthoxylum oil
- folium ginkgo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
An orally taken Chinese medicine for treating hyperlipemia is proportionally prepared from gingko leaf and Chinese picklyash oil through extracting active component of gingko leaf, and conventional process. Its advantage is high synergistic action.
Description
Technical field
The invention belongs to the medicinal preparation technical field of the product that contains raw material or itself and not clear structure, be specifically related to derive from the material of plant.
Background technology
Cardiovascular and cerebrovascular disease is to threaten one of the most serious human disease in the world today, its M ﹠ M surpasses tumor disease and leaps to the first, the active treatment hyperlipemia is the important means that the prevention cardiovascular and cerebrovascular disease reduces mortality rate, the treatment of hyperlipemia comes into one's own day by day, and blood lipid-lowering medicine has become the emphasis of modern medicines research.The Western medicine lipid lowerers is mainly based on statins, fibrate, polyunsaturated fatty acid class at present, owing to also do not have a kind of medicine to play the ability that As the medicine took effect, the symptoms lessened up till now to hyperlipemia, and lipid-regulation medicine majority commonly used clinically needs heavy dose, takes and just can keep lipid-lowering effect for a long time, and these a few class medicines all exist than serious adverse, bring many obvious toxic and side effects to patient inevitably.The Chinese medicine material that is used for cardiovascular and cerebrovascular disease mainly contains Radix Salviae Miltiorrhizae, Semen Ginkgo, Radix Puerariae, Rhizoma Chuanxiong, Radix Ilicis Pubescentis, Fructus Crataegi, Flos Carthami, Folium Perillae, Fructus Hippophae, Caulis et Folium Lini, Radix Oenotherae erythrosepalae etc., Chinese patent medicine has coronary disease No. 1, Radix Notoginseng powder, Radix Polygoni Multiflori tablet, JIANGZHILING (containing Radix Et Rhizoma Rhei and ginsenoside), compound antihyperglycemic sheet (containing the Radix Astragali, parasitism, Fructus Schisandrae Chinensis, Fructus Crataegi, Herba Taraxaci etc.) etc.But its content of drug effect components is low, and therapeutic domain is narrow, and curative effect is very not remarkable, is difficult to adapt to decentraction cerebrovascular state of an illness patient and selects for use, and cost an arm and a leg, and patient's financial burden is heavy.
Summary of the invention
Technical problem to be solved by this invention is to overcome the shortcoming of said medicine, and the medicine of a kind of toxic and side effects treatment hyperlipemia little, evident in efficacy is provided.
Solving the problems of the technologies described above the technical scheme that is adopted is: with the weight ratio of Folium Ginkgo extract and pericarpium zanthoxylum oil is 1: 2～8 proportion raw material medicinal preparation for oral administration made of formulation method routinely.
The preferred feedstock medicine weight proportion of preparation medicine of the present invention is: the weight proportion of Folium Ginkgo extract and pericarpium zanthoxylum oil is 1: 3～6.
The optimum feed stock medicine weight proportion of preparation medicine of the present invention is: the best proportioning of Folium Ginkgo extract and pericarpium zanthoxylum oil is 1: 4.
In proportioning of the present invention, used crude drug Folium Ginkgo extract is the crude drug of buying on medical market that meets the medicine regulation, the content of medicinal effective ingredient ginkgetin 〉=24% in the Folium Ginkgo extract, the content of bilobalide 〉=6%; The crude drug pericarpium zanthoxylum oil is the edible flowers pericarpium zanthoxylum oil of buying on the market, content 〉=85% of the effective medicinal components unsaturated fatty acid of pericarpium zanthoxylum oil.
The medicinal preparation for oral administration that above-mentioned each component is made according to a conventional method is said tablet or granule or a capsule on the galenic pharmacy.
The preparation technology of medicinal tablet of the present invention is as follows:
Folium Ginkgo extract and pericarpium zanthoxylum oil be mix homogeneously by weight ratio, adds starch supplementary material and stirs into pasty state, and oven dry below 60 ℃ is pulverized, and adds magnesium stearate mixing tabletting.Every heavy 0.5g, every contains crude drug 125mg.
The preparation technology of medicinal granule of the present invention is as follows:
Adjuvant that medicinal granule of the present invention is used and step of preparation process are undertaken by the conventional preparation technology of granule.Every bag heavy 2g, every gram contains crude drug 125mg.
The preparation technology of medicine capsule of the present invention is as follows:
Crude drug that medicine capsule of the present invention is used and weight proportion and medicinal tablet of the present invention are identical, and used adjuvant and other processing step are undertaken by the conventional preparation technology of capsule.Every heavy 0.4g, every contains crude drug 125mg.
Medicine of the present invention is through the test of pesticide effectiveness, experimental result shows that medicine of the present invention has therapeutical effect preferably to hyperlipemia, can reduce cholesterolemia and triglyceride level, improve hemorheology, its effect illustrates that significantly better than independent application pericarpium zanthoxylum oil or Folium Ginkgo extract pericarpium zanthoxylum oil and Folium Ginkgo extract have synergism.
The specific embodiment
The present invention is described in more detail below in conjunction with embodiment, but the invention is not restricted to these embodiment.
Embodiment 1
With 1000 of production medicinal tablet products of the present invention is that the used crude drug of example and adjuvant and proportioning thereof are:
Folium Ginkgo extract 25g
Pericarpium zanthoxylum oil 100g
Magnesium stearate 5g
Starch 370g
Its preparation technology is undertaken by the preparation technology of tablet of the present invention.Every heavy 0.5g, every contains crude drug 125mg, oral three times of every day, each 2.
With production granule product of the present invention 1000 grams is that the used crude drug of example and adjuvant and weight proportion thereof are:
Folium Ginkgo extract 25g
Pericarpium zanthoxylum oil 100g
Sucrose 400g
Dextrin 475g
Its preparation technology is undertaken by the preparation technology of granule of the present invention.Every bag heavy 2g, every gram contains crude drug 125mg, obeys each 1 bag every day three times.
With 1000 of production capsule products of the present invention is that the used crude drug of example and adjuvant and weight proportion thereof are:
Folium Ginkgo extract 25g
Pericarpium zanthoxylum oil 100g
Starch 275g
Its preparation technology is undertaken by the preparation technology of capsule of the present invention.Every heavy 0.4g, every contains crude drug 125mg, oral three times of every day, each 2.
In the proportioning of present embodiment, the weight proportion of crude drug Folium Ginkgo extract and pericarpium zanthoxylum oil is 1: 4.
Embodiment 2
With 1000 of production medicinal tablet products of the present invention is that the used crude drug of example and adjuvant and proportioning thereof are:
Folium Ginkgo extract 41.67g
Pericarpium zanthoxylum oil 83.34g
Magnesium stearate 5g
Starch adds to 500g
Its preparation technology is undertaken by the preparation technology of tablet of the present invention.Every heavy 0.5g, every contains crude drug 125mg, oral three times of every day, each 2.
With production granule product of the present invention 1000 grams is that the used crude drug of example and adjuvant and weight proportion thereof are:
Folium Ginkgo extract 41.67g
Pericarpium zanthoxylum oil 83.34g
Sucrose 400g
Dextrin adds to 1000g
Its preparation technology is undertaken by the preparation technology of granule of the present invention.Every bag heavy 2g, every gram contains crude drug 125mg, obeys each 1 bag every day three times.
With 1000 of production capsule products of the present invention is that example is raw materials used as follows with adjuvant and weight proportion thereof:
Folium Ginkgo extract 41.67g
Pericarpium zanthoxylum oil 83.34g
Starch adds to 400g
Preparation technology is undertaken by the preparation technology of capsule of the present invention.Every heavy 0.4g, every contains crude drug 125mg, oral three times of every day, each 2.
In the proportioning of present embodiment, the weight proportion of medicinal raw material Folium Ginkgo extract and pericarpium zanthoxylum oil is 1: 2.
Embodiment 3
With 1000 of production medicinal tablet products of the present invention is that the used crude drug of example and adjuvant and proportioning thereof are:
Folium Ginkgo extract 13.89g
Pericarpium zanthoxylum oil 111.12g
Magnesium stearate 5g
Starch adds to 500g
Its preparation technology is undertaken by the preparation technology of tablet of the present invention.Every heavy 0.5g, every contains crude drug 125mg, oral three times of every day, each 2.
With production granule product of the present invention 1000 grams is that the used crude drug of example and adjuvant and weight proportion thereof are:
Folium Ginkgo extract 13.89g
Pericarpium zanthoxylum oil 111.12g
Sucrose 400g
Dextrin adds to 1000g
Its preparation technology is undertaken by the preparation technology of granule of the present invention.Every bag heavy 2g, every gram contains crude drug 125mg, obeys each 1 bag every day three times.
With 1000 of production capsule products of the present invention is that the used crude drug of example and adjuvant and weight proportion thereof are:
Folium Ginkgo extract 13.89g
Pericarpium zanthoxylum oil 111.12g
Starch adds to 400g
Its preparation technology is undertaken by the preparation technology of capsule of the present invention.Every heavy 0.4g, every contains crude drug 125mg, oral three times of every day, each 2.
In the proportioning of present embodiment, the weight proportion of medicinal raw material Folium Ginkgo extract and pericarpium zanthoxylum oil is 1: 8.
In order to verify the therapeutic effect of medicine of the present invention to hyperlipemia, the inventor has carried out the test of pesticide effectiveness with the mixture (name is called silver-colored green pepper mixture during test) of the embodiment of the invention 1 proportioning preparation, and various test situation are as follows:
1, test material
Medicine of the present invention is made the test compositions by the weight proportion of embodiment 1 medicinal raw material.
Herb Gynostemmae Pentaphylli total glycosides tablet, GuangZhou BaiYunshan Chinese Medicine Factory.
Cholesterol, import packing, Tianjin chemical reagent work.
Methylthiouracil, Hongfeng Pharmaceutical Factory, lot number: 030526.
Sodium cholate, Shanghai chemical reagents corporation, lot number: 20030825.
High lipid food prescription: cholesterol 2%, Adeps Sus domestica 10%, methylthiouracil 0.1%, sodium cholate 0.2%, conventional feed 87.7%.
2, laboratory animal
Male SD rat, body weight 180～200g is provided by The Fourth Military Medical University's Experimental Animal Center, moving word 08-13 number of Shaanxi.
3, experimental apparatus
Roch automatic clinical chemistry analyzer (Switzerland).
High speed centrifugal machine for minim 3F-II (production of wheel company of Huaxing of the Ministry of Aerospace)
Low.shear300 flow graph (Switzerland contraves Co. production)
4, test method
Get 112 of healthy male SD rats, get 16 at random as the blank group, feeding normal conventional feedstuff, all the other 96 equal feeding high lipid foods, fed 30 days continuously, got each 8 of blank group and high lipid food group rats on the 31st day at random, fasting 12 hours, abdominal aortic blood behind the etherization, separation of serum is measured serum total cholesterol (TC) and triglyceride (TG).The results are shown in Table 1.
Blood lipid level (the x ± s.n=8) that table 1 is fed 30 days rats of high lipid food
| Group | ????TC(mmol/L) | ????TG(mmol/L) |
| Blank group high lipid food group | ????1.46±0.29 ????5.38±1.06*** | ????0.51±0.27 ????2.02±0.36*** |
Compare * * * P＜0.001 with the blank group.
Table 1 shows that serum cholesterol of feeding high lipid food rat and triglyceride levels are significantly higher than the rat (P＜0.001) of feeding normal diet, and hyperlipemia model modeling success is described.
Residue modeling success rat (feeding high lipid food group) 88 is divided into 11 groups at random, i.e. model group, Herb Gynostemmae Pentaphylli total glycosides tablet 30mg/kg positive controls, dosage group, 100mg/kg high dose group among medicine 25mg/kg low dose group of the present invention, the 50mg/kg; Dosage group, 100mg/kg high dose group dosage group among pericarpium zanthoxylum oil 25mg/kg low dose group, the 50mg/kg, dosage group, 100mg/kg high dose group among Folium Ginkgo extract 25mg/kg low dose group, the 50mg/kg, 8 every group.Each group is irritated stomach respectively and is given normal saline (blank group and model group), and the medicine of corresponding dosage, every day 1 time, successive administration 20 days, fasting is 12 hours after the last administration, abdominal aortic blood behind the etherization, part blood system are from determination of serum serum total cholesterol (TC) and triglyceride (TG), and a part of in addition anticoagulant heparin is surveyed hemorheology.
5, result of the test: result of the test sees Table 2.
Table 2 medicine of the present invention to the effect of hyperlipidemia rats blood fat (x ± s, n=8)
| Dosage (mg/kg) | ????TC(mmol/L) | ????TG(mmol/L) | |
| Blank model group Herb Gynostemmae Pentaphylli total glycosides tablet medicine of the present invention medicine of the present invention medicine pericarpium zanthoxylum oil of the present invention pericarpium zanthoxylum oil pericarpium zanthoxylum oil ginkgo biloba p.e ginkgo biloba p.e ginkgo biloba p.e | ????30 ????25 ????50 ????100 ????25 ????50 ????100 ????25 ????50 ????100 | ????1.54±0.36 ????6.14±0.48 ▲▲▲????????3.98±0.40 ***????5.68±0.49 ????3.47±0.34 ***????2.26±0.39 ***????6.32±0.56 ????5.58±0.42 *????4.96±0.51 ***????6.36±0.33 ????5.04±0.66 **????3.97±0.649 *** | ????0.61±0.18 ????2.51±0.22 ▲▲▲????????1.43±0.25 ***????2.48±0.31 ????1.67±0.16 ***????0.98±0.19 ***????2.50±0.28 ????2.25±0.21 *????1.98±0.35 **????2.44±0.22 ????2.05±0.24 **????1.62±0.16 *** |
Compare with the blank group:
▲ ▲ ▲P＜0.001; Compare with model group: * P＜0.05, * P＜0.01, * * * P＜0.001.
The result shows that the middle and high dosage group of medicine of the present invention can significantly reduce the serum TC value and the TG value (P＜0.001) of hyperlipidemia rats; Use pericarpium zanthoxylum oil or Folium Ginkgo extract separately and also can reduce serum TC and TG (P＜0.05, P＜0.01 or P＜0.001), but curative effect is low than medicine of the present invention at middle high dose.
Table 3 medicine of the present invention to the effect of hyperlipidemia rats hemorheology (x ± s, n=8)
| Dosage (mg/kg) | Plasma viscosity (mPa.s) | The whole blood height is cut viscosity (mPa.s) | The low viscosity (mPa.s) of cutting of whole blood | Erythrocyte aggregation index | |
| Blank model group Herb Gynostemmae Pentaphylli total glycosides tablet medicine of the present invention medicine of the present invention medicine pericarpium zanthoxylum oil of the present invention ginkgo biloba p.e | ????30 ????25 ????50 ????100 ????50 ????50 | ????1.30±0.03 ????1.60±0.06 ▲▲????????1.44±0.05 *????1.52±0.01 *????1.48±0.03 **????1.34±0.03 **????1.50±0.05 *????1.48±0.06 ** | 4.43±0.21 5.48±0.06 ▲▲▲5.19±0.39 5.37±0.22 4.76±0.18 **4.49±0.23 ***4.95±0.21 *4.86±0.29 * | ??13.23±1.13 ??18.36±0.69 ▲▲▲????15.35±0.95 **??15.99±0.78 **??14.36±1.06 **??13.69±0.48 ***??15.21±0.65 **??14.89±0.48 ** | ??2.20±0.32 ??5.34±0.32 ▲▲▲????3.27±0.16 ***??3.41±0.12 ***??2.96±0.21 ***??2.42±0.33 ***??3.35±0.31 ***??3.01±0.28 *** |
Compare with the blank group:
▲ ▲P＜0.01,
▲ ▲ ▲P＜0.001; Compare with model group:
*P＜0.05,
*P＜0.01,
* *P＜0.001.
The result shows, medicine of the present invention can significantly reduce the hyperlipidemia rats plasma viscosity, high and low viscosity and the erythrocyte aggregation cut of whole blood improves significantly to the hyperlipidemia rats hemorheology, and effect is better than the effect of using pericarpium zanthoxylum oil or Folium Ginkgo extract with dosage separately.
6, conclusion (of pressure testing)
Medicine of the present invention has therapeutical effect preferably to hyperlipemia, can reduce cholesterolemia and triglyceride level, improve hemorheology, it acts on significantly better than independent application pericarpium zanthoxylum oil or Folium Ginkgo extract, illustrates that pericarpium zanthoxylum oil and Folium Ginkgo extract have synergism.
Function of the present invention: reduce serum cholesterol and triglyceride levels, improve hemorheology.
The present invention cures mainly: hyperlipemia.
Specification of the present invention: every heavy 0.5g of medicinal tablet of the present invention, every contains crude drug 125mg; Every bag heavy 2g of medicinal granule of the present invention, every bag contains crude drug 250mg; Every heavy 0.4g of medicine capsule of the present invention, every contains crude drug 125mg.
Usage and dosage of the present invention: obey 1 bag of 2 of each oral tablets or 2 of capsules or granule every day three times.
Storage of the present invention: the shady and cool dry place of sealing storage.
Effect duration of the present invention: 5 years.
Claims (3)
1, a kind of oral drugs for the treatment of hyperlipemia is characterized in that: it is that weight ratio with crude drug Folium Ginkgo extract and pericarpium zanthoxylum oil is 1: 2～8 to be the raw material medicinal preparation for oral administration made of formulation method routinely.
2, according to the described a kind of oral drugs for the treatment of hyperlipemia of claim 1, it is characterized in that: wherein the weight proportion of crude drug Folium Ginkgo extract and pericarpium zanthoxylum oil is 1: 3～6.
3, according to the described a kind of oral drugs for the treatment of hyperlipemia of claim 1, it is characterized in that: wherein the weight proportion of crude drug Folium Ginkgo extract and pericarpium zanthoxylum oil is 1: 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100416272A CN100364579C (en) | 2005-01-14 | 2005-01-14 | Oral medicine for treating hyperlipemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100416272A CN100364579C (en) | 2005-01-14 | 2005-01-14 | Oral medicine for treating hyperlipemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1679822A true CN1679822A (en) | 2005-10-12 |
| CN100364579C CN100364579C (en) | 2008-01-30 |
Family
ID=35066828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100416272A Expired - Fee Related CN100364579C (en) | 2005-01-14 | 2005-01-14 | Oral medicine for treating hyperlipemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100364579C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102138575A (en) * | 2010-12-31 | 2011-08-03 | 颜平安 | Spina date seed/oil food with functions of tranquilizing mind, lowering lipid and preventing cancers and processing method thereof |
| CN106265824A (en) * | 2015-06-17 | 2017-01-04 | 海南医学院 | The application in preparation treatment hyperlipidemia of the fujian tea extract |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1159047C (en) * | 2002-01-18 | 2004-07-28 | 北京大学 | Active components of Chinese-medicinal medicine with weight-losing and hypolipemic actions and its relative medicine |
-
2005
- 2005-01-14 CN CNB2005100416272A patent/CN100364579C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102138575A (en) * | 2010-12-31 | 2011-08-03 | 颜平安 | Spina date seed/oil food with functions of tranquilizing mind, lowering lipid and preventing cancers and processing method thereof |
| CN106265824A (en) * | 2015-06-17 | 2017-01-04 | 海南医学院 | The application in preparation treatment hyperlipidemia of the fujian tea extract |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100364579C (en) | 2008-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1907462A (en) | Traditional Chinese medicine composition for treating hepatitis and fatty liver | |
| CN102145159A (en) | Ginger and elecampane composition, preparation method of ginger and elecampane composition and use of ginger and elecampane composition for preparing toxicity-reducing efficacy-improving medicine in cancer radiotherapy and chemotherapy | |
| CN1824211A (en) | Lung clearing cough suppressing phlegm transforming medicinal preparation and its new preparation method | |
| CN1561994A (en) | Medicinal compositon containing artemisine extract for treating rheumatoid arthritis and immunologic disease | |
| CN1895462A (en) | Nankang soft capsule for treating prostatitis | |
| CN1923193A (en) | Application of cumarin kind compound in preparation of antiphlogistic and analgetic medicine | |
| CN1283281C (en) | Medicinal composition containing wild jujube seed, lucid ganoderma and ginseng leaf and its preparing process and use | |
| CN1679822A (en) | Oral medicine for treating hyperlipemia | |
| CN1788755A (en) | Framberry leaf extract effective part and its composition and uses | |
| CN1733286A (en) | A kind of compound Chinese medicinal preparation of preventing and treating alcoholic intestinal tract damage and hepatic injury | |
| CN1824018A (en) | Dual supplementation preparation of qi and blood and its making method | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN1286501C (en) | Medicine composition for treating stomach disease, its preparation method and use | |
| CN1839956A (en) | Pharmaceutical composition containing curcumin and its formulation | |
| CN1879799A (en) | Menstruation-regulating preparation with asiabell and cassia bark and method for preparing same | |
| CN1824100A (en) | Medicinal preparation for treating cough and panting and its preparation method | |
| CN1159029C (en) | Blood lipoid regulating medicine and its prepn | |
| CN100345534C (en) | Yinzhi huang capsule, its preparation method and use | |
| CN102552847B (en) | Ginger and inula flower composition for reducing vomiting caused by cancer chemotherapy and increasing curative effect for chemotherapy and preparing method thereof | |
| CN1199683C (en) | Medicine combination for reducing blood fat and preventing senescence and its medicines | |
| CN101062097A (en) | Compound for improving and treating fatty liver disease | |
| CN1824079A (en) | Anti appendicitis preparation and its new preparation method | |
| CN1799603A (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN1233403C (en) | Medicine for preventing and treating chicken influenza | |
| CN109316565A (en) | A kind of blood-fat reducing composition and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |